Mode of early relapse in resectable I-IIIA NSCLC – prospective, controlled study

D. R. Subotich, D. V. Mandarich, N. D. Atanasijadis, L. M. Andrich, J. R. Stojsich (Belgrade, Serbia And Montenegro)

Source: Annual Congress 2005 - Tracheal surgery, emergencies and infectious problems
Session: Tracheal surgery, emergencies and infectious problems
Session type: Thematic Poster Session
Number: 1098
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. R. Subotich, D. V. Mandarich, N. D. Atanasijadis, L. M. Andrich, J. R. Stojsich (Belgrade, Serbia And Montenegro). Mode of early relapse in resectable I-IIIA NSCLC – prospective, controlled study. Eur Respir J 2005; 26: Suppl. 49, 1098

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial
Source: Eur Respir J 2007; 30: Suppl. 51, 240s
Year: 2007

Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Long-term survivors in stage IIIB/IV lung cancer – a 5 year retrospective analysis
Source: Eur Respir J 2007; 30: Suppl. 51, 432s
Year: 2007

Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors
Year: 2008


Phase II study of cisplatin-vinorelbine sequenced by gemcitabine-vinorelbine in patients with unresectable non-small-cell lung cancer (NSCLC): preliminary results
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003

A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902)
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Retrospective assessment of non small cell lung cancer stage IIIA-IIIB, treated with neoadjuvant chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010


Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018




Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study
Source: Eur Respir J, 50 (6) 1701493; 10.1183/13993003.01493-2017
Year: 2017



Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008

Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017




Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 241s
Year: 2007

Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC)
Source: Annual Congress 2003 - Advanced lung cancer treatment
Year: 2003


The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007


A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005


Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003

Bevacizumab as first line treatment for advanced non-small cell lung cancer (NSCLC): a meta-analysis of randomised placebo-controlled trials (RCTs)
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008



The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting
Source: Eur Respir J 2002; 20: Suppl. 38, 399s
Year: 2002